NASDAQ:FIXX

Homology Medicines Earning Date

USA |NASDAQ |USD

FIXX Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 8, 2021 Sep 2021 $-0.60 $-0.54 $-0.62
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 8, 2021 Sep 2021 $720.00K $2.19M $567.00K

Homology Medicines's next earnings date is Monday, Nov 8, 2021 for the fiscal quarter ending Sep 2021.

FIXX Earnings Date & History Chart

FIXX Earnings & Revenue Forecast

FIXX Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 9 $-0.61 $-0.74 $-0.40
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 9 $-1.80 $-2.04 $-1.47
Dec 2022 9 $-2.40 $-3.00 $-1.98

FIXX Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-0.61 $-0.60 $-0.61
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-1.80 $-1.84 $-1.86
Dec 2022 0 / 0 $-2.40 $-2.34 $-2.44

FIXX Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 9 $720.00K $0.00 $2.20M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 8 $32.90M $31.50M $35.90M
Dec 2022 9 $2.94M $0.00 $8.70M

FIXX Earnings Date & Revenue History

FIXX Earnings History

|
Show More
Show More

FIXX Revenue History

|
Show More
Show More

Homology Medicines Next Earnings Date & Report

FIXX Next Earnings Date & Report Preview: Sep 2021 (FQ)

FIXX's next earnings date is Monday, Nov 8, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 9 analysts, the average EPS estimation for Homology Medicines's next quarterly earnings is $-0.60, with a low EPS estimation of $-0.71, and a high estimation of $-0.51.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.60, the last 2 month trend is $-0.61, and the 3 month trend is $-0.61.

Based on 9 analysts, the average revenue estimation is $720.00K, with a low revenue estimation of $0.00, and a high estimation of $2.20M.

Homology Medicines Previous Earnings Dates & Reports

FIXX Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Homology Medicines's previous earnings date was Aug 12, 2021 for its fiscal quarter ended Jun 30, 2021.

FIXX's earnings per share (EPS) was $-0.54, beating the consensus analysts forecast of $-0.60 by 10.37%.

The EPS was lower than the previous fiscal quarter (Mar 2021) by 2600.00%, and higher than the same period a year before (Jun 2020) by -30.77%.

Revenues were $2.19M, better than the forecast of $2.19M by 0.00%, down by -92.54% from the previous quarter , and up by 285.71% from the same period last year.

The company reported a net income of $-30.50M.

Free cash flow for the quarter was $-24.88M , compared to $-30.64M last quarter and $-28.57M a year before.

FIXX ended the quarter with $14.19M in total debt, a decrease of -4.26% compared to the previous quarter, and a decrease of -14.54% compared to the same quarter a year before.

FIXX Previous Earnings Date & Report Recap: Dec 2020 (FY)

Homology Medicines's previous annual earnings date was Mar 11, 2021 for its fiscal year ended Dec 31, 2020.

FIXX's earnings per share (EPS) was $-2.80, beating the consensus analysts forecast of $-2.89 by -3.11% , and lower than the previous year's EPS (Dec 2019) by 13.36%.

Revenues were $2.70M, worse than the forecast of $2.84M by -4.86%, and up by 62.18% from previous year's revenue.

The company reported a net income of $-128.69M.

Homology Medicines reported a free cash flow of $-98.06M for its fiscal year, compared to $-113.19M a year ago.

The company ended the fiscal year with $15.44M in total debt. lala